After Pharvaris N.V. (NASDAQ:PHVS), its Dutch competitor in hereditary angioedema (HAE), placed an FDA clinical hold on its lead asset, PHA121, the shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) rose to their highest level since March on Monday.
For the uncommon inherited blood condition HAE, two Investigational New Drug (IND) applications have been submitted for the oral bradykinin B2-receptor antagonist PHA121.
KalVista (KALV) is also developing KVD900, oral medicine for HAE, and is currently at a global late stage; results are anticipated in the second half of 2023.
According to Stifel analyst Paul Matteis, who has a Buy rating and $32 on KALV, the event will continue to be an overhang to some extent even if PHVS releases its clinical hold on its HAE candidate and “position KALV favorably if clinical data next year play out as we think.”
KalVista Pharmaceuticals, Inc
The goal of KalVista Pharmaceuticals, Inc., a pharmaceutical firm, is to find, create, and market oral, small-molecule protease inhibitors for conditions with high unmet medical needs. Hereditary angioedema (HAE) and diabetic macular edema are the initial targets of the innovative, small molecule plasma kallikrein inhibitors that KalVista has developed (DME). Sebetralstat is being developed by KalVista as an oral on-demand treatment for acute HAE attacks, and the Phase 3 KONFIDENT clinical trial has begun
The Phase 2 KOMPLETE clinical trial of KVD824 is now being conducted with the goal of treating HAE prophylactically. A new line of treatments, including KalVista’s oral Factor XIIa inhibitor program, may also help patients receive better care for HAE. KVD001, a plasma kallikrein inhibitor delivered intravitreally, has finished a Phase 2 clinical trial in DME.
Institutional Interest
Institutional investors and hedge funds recently changed how much of the stock they were holding. In the second quarter, Walleye Capital LLC increased its holdings in KalVista Pharmaceuticals by 218.2%. After purchasing an additional 140,128 shares in the most recent quarter, Walleye Capital LLC now owns 204,338 shares of the specialty pharmaceutical company’s stock, valued at $2,011,000. In the second quarter, Goldman Sachs Group Inc. increased its holdings in KalVista Pharmaceuticals shares by 80.7%. After purchasing an additional 134,570 shares in the most recent quarter, Goldman Sachs Group Inc. now owns 301,275 shares of the specialty pharmaceutical company’s stock, valued at $2,965,000. In the second quarter, Woodline Partners LP increased its holdings in KalVista Pharmaceuticals by 118.7%. After purchasing an additional 589,869 shares in the most recent quarter, Woodline Partners LP now owns 1,086,883 shares of the specialty pharmaceutical company’s stock, valued at $10,695,000. More institutional investment reporting here.
Featured Image: Megapixl @Jgroup
Author Jowi Kwasu 
